Tumor Immunology

肿瘤免疫学

基本信息

批准号：
10619463
负责人：
ANTONI RIBAS
金额：
$ 14.53万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
1996
资助国家：
美国
起止时间：
1996-12-01 至 2025-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10619463
关键词：
AIDS related cancer Achievement Adoptive Cell Transfers American Association of Cancer Research Antibodies Area Asian population Award B-Cell Lymphomas Biomedical Engineering CD19 gene Cancer Burden Cancer Center Support Grant Catchment Area Cell Therapy Cells Cellular biology Chimeric Proteins Clinical Clinical Research Clinical Trials Collaborations Colorectal Community Outreach Comprehensive Cancer Center County Creativeness Development Direct Costs Doctor of Philosophy Education Engineering Environment Flow Cytometry Shared Resource Fostering Funding Funding Mechanisms Genes Genetic Engineering Goals Good Manufacturing Process Hematologic Neoplasms Human Immune Immune checkpoint inhibitor Immune system Immunologic Monitoring Immunology Immunosuppression Immunotherapy Incidence Inflammation Infrastructure Institution Intervention Journals Laboratory Finding Latino Population Lead Los Angeles Lung Lymphoma Malignant Neoplasms Malignant neoplasm of brain Malignant neoplasm of liver Malignant neoplasm of lung Malignant neoplasm of pancreas Medicine Mentors Mission Monoclonal Antibodies Natural Killer Cells Patients Peer Review Pharmaceutical Preparations Postdoctoral Fellow Pre-Clinical Model Prostate Proteins Publications Publishing Regulation Renal carcinoma Research Research Personnel Resistance Resource Sharing Resources Route Schools Science Series Site Small Animal Imaging Shared Resource T cell response T-Cell Receptor T-Lymphocyte Testing Therapeutic Therapeutic antibodies Training Training Programs Training and Education Translating Translations Tumor Antigens Tumor Cell Biology Tumor Escape United States National Institutes of Health Work anti-tumor immune response antibody conjugate anticancer research antigen-specific T cells cancer cell cancer immunotherapy cancer therapy career cellular imaging checkpoint receptors chimeric antigen receptor chimeric antigen receptor T cells clinical translation cohesion collaborative environment combinatorial community engagement cytokine engineered T cells ethnic minority population frontier graduate student immune checkpoint blockade immunotherapy clinical trials immunotherapy trials improved in vivo kinase inhibitor malignant stomach neoplasm manufacture meetings melanoma member multidimensional data non-invasive imaging novel preclinical study programs recruit response small molecule supportive environment synthetic biology targeted agent therapeutic protein translational physician translational scientist tumor tumor immunology tumor microenvironment whole body imaging

项目摘要

TUMOR IMMUNOLOGY RESEARCH PROGRAM (TI) ABSTRACT AACR president-elect Antoni Ribas, MD, PhD (Director) together with T cell engineer Yvonne Chen, PhD (Co- Director) lead the UCLA Jonsson Comprehensive Cancer Center (JCCC) Tumor Immunology Research Program (TI). Ribas and Chen stimulate Program cohesion and goal-oriented achievement through two independent but related objectives, which are to provide a highly interactive and supportive environment that deepens member understanding of tumor immunology, and to develop novel immune-based therapies for patients with cancer. TI brings basic and translational scientists together, guided by Los Angeles County (LAC) catchment area needs and priorities, to spawn novel investigator-initiated immunotherapy clinical trials in melanoma, lymphoma, brain, lung, and kidney cancer, and other tumor types. There are many TI Program strengths, including in the following nine areas. (1) Bringing new cancer immunotherapies to drug regulatory approval. (2) Uncovering mechanisms of response and resistance to immune checkpoint blockade. (3) Clinical trials of genetically engineered T cells and their precursors with T cell receptors (TCRs) or chimeric antigen receptors (CARs) to generate cancer- directed immune systems. (4) Non-invasive imaging of tumor antigen-specific T cell distributions and tumor targeting in vivo. (5) Engineering new platforms for immune monitoring of T cell responses to cancer. (6) Examining the relationship between inflammation and cancer. (7) Generating and using antibody fusion proteins for cancer therapy. (8) Investigating therapeutic combinations with targeted agents to sensitize cancer cells to immunotherapy. (9) Studies aiming to improve the lives of patients with AIDS-related cancers. These nine and additional basic and translational Program strengths rely heavily upon a CCSG-funded infrastructure and all six JCCC Shared Resources. The Flow Cytometry Shared Resource (FCSR) is the most active core and the Small Animal Imaging Shared Resource (SAISR) enables T cell imaging projects that move from preclinical models to patients. Outside of the six official JCCC Shared Resources is the JCCC/Human Gene Medicine Program Good Manufacturing Practices (GMP) facility, which TI investigators use to manufacture personalized cell products in- house, meeting local, state, and federal regulations for use in humans. The TI Program has 31 members from 11 departments in four schools at UCLA and affiliate, Caltech. As of March 1, 2019, the Program had $19,280,597 in direct cost funding, including $4,823,507 (25%) from the NCI, and $14,028,565 (73%) in direct cost peer-reviewed funding. Program discoveries resulted in 627 publications, with 13% from intra-programmatic and 37% from inter-programmatic collaborations. In addition, 57% of publications are from collaborations with external institutions and 44% are in high-impact (IF ≥10, or field leading) journals. Impactful Program research yielded paradigm shifting discoveries in mechanisms of immunotherapy resistance and practice changing advances with three FDA approvals since 2014, the first FDA approvals for immune checkpoint inhibitors in cancer, for melanoma and lung cancer, and FDA approval for anti-CD19 CAR-T cells in large B cell lymphoma.

肿瘤免疫研究计划（TI）抽象的 AACR当选总统Antoni Ribas，医学博士，博士（主任）与T细胞工程师Yvonne Chen博士（共同）导演）领导加州大学洛杉矶分校乔森森综合癌症中心（JCCC）肿瘤免疫学研究计划（ti）。 Ribas和Chen通过两个独立但以目标的成就刺激了计划的凝聚力和面向目标的成就相关对象，这些物体提供一个高度互动和支持的环境，使成员加深了解肿瘤免疫学，并为癌症患者开发新的基于免疫的疗法。 ti 在洛杉矶县（LAC）集水区需要的指导下，将基本和翻译的科学家汇集在一起和优先事项，用于产生新型研究者发起的免疫疗法临床试验肺，肾癌和其他肿瘤类型。有许多TI计划的优势，包括以下内容九个地区。（1）将新的癌症免疫疗法带到药物调节批准中。（2）发现机制（3）基因工程T细胞的临床试验及其与T细胞受体（TCRS）或嵌合抗原受体（CAR）的前体，以产生癌症 - 定向免疫系统。（4）肿瘤抗原特异性T细胞分布和肿瘤的非侵入性成像靶向体内。（5）工程新平台，用于免疫对T细胞对癌症反应的反应。（6）检查炎症与癌症之间的关系。（7）生成和使用抗体融合蛋白用于癌症治疗。（8）研究与靶向剂的治疗组合，以将癌细胞感知到免疫疗法。（9）旨在改善与艾滋病相关癌症患者的生活的研究。这九个其他基本和翻译的计划优势在很大程度上取决于CCSG资助的基础设施和所有六个 JCCC共享资源。流式细胞仪共享资源（FCSR）是最活跃的核心，很小动物成像共享资源（SAISR）使T细胞成像项目从临床前模型转变为患者。 JCCC/Human Gene Medicine Program在六个官方共享资源之外制造实践（GMP）设施，TI调查人员用它来制造个性化的细胞产品众议院，符合当地，州和联邦法规，以供人类使用。 TI计划有31名成员加州大学加州大学加州大学洛杉矶分校的四所学校的11个部门。截至2019年3月1日，该计划已有 $ 19,280,597的直接成本资金，包括NCI的$ 4,823,507（25％），直接筹集$ 14,028,565（73％）经过同行评审的资金。程序发现产生了627个出版物，其中13％来自策略和37％的程序间合作。此外，有57％的出版物来自与外部机构和44％处于高影响力（如果≥10或田间领先）期刊中。有影响力的计划研究在免疫疗法的机制中产生了范式转移的发现，并改变了练习自2014年以来，获得了三项FDA批准的进步，这是对免疫检查点抑制剂的首次FDA批准癌症，用于黑色素瘤和肺癌，以及大型B细胞淋巴瘤中抗CD19 CAR-T细胞的FDA批准。